/DYN
DYN Stock - Dyne Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$17.04-2.41%
$0.42 (-2.41%) • Jan 13
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+113.4%upside
Target: $36.36
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DYN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.87 – $17.21
TARGET (TP)$36.36
STOP LOSS$15.68
RISK/REWARD1:14.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.32
52W High$25.00
52W Low$6.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-2,243,000 | $-2,461,000 | N/A | N/A | $-700,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-343,886,000 | $-242,162,000 | $-170,962,000 | $-150,025,000 | $-58,647,000 |
| Net Income | $-317,418,000 | $-235,937,000 | $-168,099,000 | $-149,291,000 | $-58,737,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.37 | $-3.95 | $-3.23 | $-2.93 | $-1.24 |
Company Overview
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
DYNBeat Rate
39%
Last 18 quarters
Avg Surprise
-6.7%
EPS vs Estimate
Beats / Misses
7/10
1 met exactly
Latest EPS
$-0.76
Q4 2025
EPS Surprise History
Q1 24
-18.5%
$-1.09vs$-0.92
Q2 24
0.0%
$-0.81vs$-0.81
Q3 24
+2.8%
$-0.70vs$-0.72
Q4 24
-35.2%
$-0.96vs$-0.71
Q1 25
+4.3%
$-0.88vs$-0.92
Q2 25
-19.3%
$-1.05vs$-0.88
Q3 25
+2.0%
$-0.97vs$-0.99
Q4 25
+6.2%
$-0.76vs$-0.81
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.74 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.81 | $-0.76 | +6.2% | ✓ BEAT |
Q3 2025 | Jul 28, 2025 | $-0.99 | $-0.97 | +2.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.88 | $-1.05 | -19.3% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.92 | $-0.88 | +4.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.71 | $-0.96 | -35.2% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.72 | $-0.70 | +2.8% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.81 | $-0.81 | 0.0% | = MET |
Q1 2024 | Mar 5, 2024 | $-0.92 | $-1.09 | -18.5% | ✗ MISS |
Q4 2023 | Oct 30, 2023 | $-0.86 | $-0.99 | -15.1% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.81 | $-1.08 | -33.3% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.77 | $-0.78 | -1.3% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.84 | $-0.74 | +11.9% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.95 | $-0.80 | +15.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.79 | $-1.01 | -27.8% | ✗ MISS |
Q2 2022 | May 2, 2022 | $-0.88 | $-0.69 | +21.6% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.99 | $-1.00 | -1.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.65 | $-0.83 | -27.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.55 | $-0.58 | -5.5% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about DYN
What is DYN's current stock price?
Dyne Therapeutics, Inc. (DYN) is currently trading at $17.04 per share. The stock has moved -2.41% today.
What is the analyst price target for DYN?
The average analyst price target for DYN is $36.36, based on 1 analyst.
What sector is Dyne Therapeutics, Inc. in?
Dyne Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DYN's market cap?
Dyne Therapeutics, Inc. has a market capitalization of $2.43 billion, making it a mid-cap company.
Does DYN pay dividends?
No, Dyne Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$27.77
Mkt Cap: $2.6B
APGE
Apogee Therapeutics, Inc.
$79.00
Mkt Cap: $4.3B
CELC
Celcuity Inc.
$104.21
Mkt Cap: $4.8B
CGON
CG Oncology, Inc. Common stock
$52.58
Mkt Cap: $3.9B
CNTA
Centessa Pharmaceuticals plc
$22.22
Mkt Cap: $3.0B
MIRM
Mirum Pharmaceuticals, Inc.
$90.44
Mkt Cap: $4.5B
RARE
Ultragenyx Pharmaceutical Inc.
$24.11
Mkt Cap: $2.3B
SLNO
Soleno Therapeutics, Inc.
$41.51
Mkt Cap: $2.2B
TLX
Telix Pharmaceuticals Limited
$7.45
Mkt Cap: $2.5B
XENE
Xenon Pharmaceuticals Inc.
$40.36
Mkt Cap: $3.1B
Explore stocks similar to DYN for comparison